Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -114.48% is 75% above its 5-year average of -465.16%, near the high end of its 5-year range (-2202.50%–137.79%).
As of the fiscal period ended Wednesday, December 31, 2025. 10.33% above its 12-month average of -127.66%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-114.48%
RETURN ON EQUITY (ROE) AVG TTM
-127.66%
RETURN ON EQUITY (ROE) AVG 3Y
-155.08%
RETURN ON EQUITY (ROE) AVG 5Y
-465.16%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.33%
CURRENT VS 3Y AVG
+26.18%
CURRENT VS 5Y AVG
+75.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 658 covered companies
CURRENT VS SECTOR MEDIAN
-184.03%
vs the sector median at left
NewcelX Ltd.
Market Cap
$1.33M
Return on Equity (ROE)
-114.48%
TTM Avg
-127.66%
3Y Avg
-155.08%
5Y Avg
-465.16%
Market Cap
$1.34M
Return on Equity (ROE)
-111.51%
TTM Avg
-753.43%
3Y Avg
-507.39%
5Y Avg
-356.28%
Market Cap
$1.38M
Return on Equity (ROE)
-253.57%
TTM Avg
334.28%
3Y Avg
134.39%
5Y Avg
95.16%
Market Cap
$1.44M
Return on Equity (ROE)
-124.97%
TTM Avg
-62.14%
3Y Avg
-63.41%
5Y Avg
-579.67%
Market Cap
$1.43M
Return on Equity (ROE)
-32.05%
TTM Avg
-197.10%
3Y Avg
-44.98%
5Y Avg
-69.38%
Market Cap
$1.20M
Return on Equity (ROE)
N/A
TTM Avg
206.72%
3Y Avg
141.32%
5Y Avg
115.74%
Market Cap
$1.18M
Return on Equity (ROE)
-200.63%
TTM Avg
-312.18%
3Y Avg
-122.70%
5Y Avg
-56.14%
Market Cap
$1.48M
Return on Equity (ROE)
-169.64%
TTM Avg
97.92%
3Y Avg
65.28%
5Y Avg
65.28%
Market Cap
$1.48M
Return on Equity (ROE)
-80.57%
TTM Avg
-96.07%
3Y Avg
-115.92%
5Y Avg
51.19%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewcelX Ltd. (NCEL) | $1.33M | -114.48% | -127.66% | -155.08% | -465.16% |
| Genprex, Inc. (GNPX)vs › | $1.34M | -111.51% | -753.43% | -507.39% | -356.28% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | -253.57% | 334.28% | 134.39% | 95.16% |
| NEXGEL, Inc. (NXGL)vs › | $1.44M | -124.97% | -62.14% | -63.41% | -579.67% |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | -32.05% | -197.10% | -44.98% | -69.38% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.20M | N/A | 206.72% | 141.32% | 115.74% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.18M | -200.63% | -312.18% | -122.70% | -56.14% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.48M | -169.64% | 97.92% | 65.28% | 65.28% |
| PMGC Holdings Inc. (ELAB)vs › | $1.48M | -80.57% | -96.07% | -115.92% | 51.19% |
| Curis, Inc. (CRIS)vs › | $1.50M | -450.54% | 292.29% | 55.45% | 24.80% |
ROE
-114.5%
ROA
-72.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -114.48% |
| 2024-12-31 | -140.85% |
| 2023-12-31 | 137.79% |
| 2022-12-31 | -502.79% |
| 2021-12-31 | -2202.50% |
| 2020-12-31 | 31.85% |
| 2019-12-31 | 88.27% |
| 2018-12-31 | 0.06% |
| 2017-12-31 | 86.26% |
